◎ Sugi Atlas

Atlas / Drug / Mirabegron

Mirabegron

drug
On this page

Also known as BetanisBetmigaMyrbetriqMyrbetriq granulesYM-178YM178MIRABEGRON (YM178)MirabegronÊMirabegronÂ

Summary

Mirabegron (CHEMBL2095212) is an approved small-molecule β-adrenergic agonist (ATC G04BD12) targeting ADRB1, ADRB2, and ADRB3; indicated across 16 conditions including overactive bladder and interstitial cystitis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G04BD12
  • Targets: 3 (ADRB1, ADRB2, ADRB3)
  • Indications: 16 conditions
  • Clinical trials: 153
  • Chemistry: 396.5 Da · C21H24N4O2S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2095212
NameMirabegron
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID9865528
ChEBICHEBI:65349
ATCG04BD12
Molecular formulaC21H24N4O2S
Molecular weight396.5
InChIKeyPBAPPPCECJKMCM-IBGZPJMESA-N

SMILES: C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O

IUPAC name: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide

ChEBI definition: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol. Used for the treatment of overactive bladder syndrome.

Pharmacological roles (ChEBI): β-adrenergic agonist.

Also known as: Betanis, Betmiga, Mirabegron, Myrbetriq, Myrbetriq granules, YM-178, YM178, MIRABEGRON, mirabegron, MIRABEGRON (YM178), MirabegronÊ, Mirabegron (YM178)

Parent form; salt/anhydrous children: CHEMBL3542362

Patent coverage: 514 distinct patent families (1,038 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADRB1β1-adrenoceptorAgonist50%P08588
ADRB2β2-adrenoceptorAgonist50.4%P07550
ADRB3β3-adrenoceptorAgonist8.80.1%P13945

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-3 adrenergic receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ADRB37.65EC5022.4nMCHEMBL_ACT_25708405

Target pathways

Aggregated over 3 target gene(s): ADRB1, ADRB2, ADRB3.

Top Reactome pathways

16 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction3ADRB1, ADRB2, ADRB3
Signaling by GPCR3ADRB1, ADRB2, ADRB3
Class A/1 (Rhodopsin-like receptors)3ADRB1, ADRB2, ADRB3
Amine ligand-binding receptors3ADRB1, ADRB2, ADRB3
GPCR downstream signalling3ADRB1, ADRB2, ADRB3
Adrenoceptors3ADRB1, ADRB2, ADRB3
G alpha (s) signalling events3ADRB1, ADRB2, ADRB3
GPCR ligand binding3ADRB1, ADRB2, ADRB3
Membrane Trafficking1ADRB2
Metabolism of proteins1ADRB2
Vesicle-mediated transport1ADRB2
Deubiquitination1ADRB2
Ub-specific processing proteases1ADRB2
Post-translational protein modification1ADRB2
Cargo recognition for clathrin-mediated endocytosis1ADRB2
Clathrin-mediated endocytosis1ADRB2

Dominant GO biological processes

GO termTargets
diet induced thermogenesis3
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure3
adenylate cyclase-activating G protein-coupled receptor signaling pathway3
response to cold3
heat generation3
negative regulation of multicellular organism growth3
positive regulation of MAPK cascade3
brown fat cell differentiation3
adenylate cyclase-activating adrenergic receptor signaling pathway3
positive regulation of cold-induced thermogenesis3
signal transduction3
G protein-coupled receptor signaling pathway3
positive regulation of cardiac muscle cell apoptotic process2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway2
negative regulation of smooth muscle contraction2

Indications & clinical

Indications

16 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
overactive bladder4MONDO:0006624EFO:1000781
interstitial cystitis3MONDO:0018301EFO:1000869
nephrolithiasis3MONDO:0008171EFO:0004253
heart failure2MONDO:0005252EFO:0003144
prediabetes syndrome2MONDO:0006920EFO:1001121
intracerebral hemorrhage2MONDO:0013792EFO:0005669
liver disorder1MONDO:0005154EFO:0001421
polycystic ovary syndrome1MONDO:0008487EFO:0000660
kidney disorder1MONDO:0005240EFO:0003086

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 153.

Phase distribution

PhaseTrials
PHASE438
PHASE133
PHASE328
PHASE226
Not specified18
EARLY_PHASE15
PHASE1/PHASE23
PHASE2/PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05051436PHASE4RECRUITINGThe Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
NCT05362292PHASE4RECRUITINGTReating Incontinence for Underlying Mental and Physical Health
NCT05604222PHASE4ACTIVE_NOT_RECRUITINGEffect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women
NCT06465576PHASE4RECRUITINGStrategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
NCT06479720PHASE4RECRUITINGEfficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
NCT07187466PHASE4NOT_YET_RECRUITINGBehavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
NCT07310797PHASE4NOT_YET_RECRUITINGComparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion
NCT01745094PHASE4COMPLETEDA Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NCT01964183PHASE4COMPLETEDPost-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
NCT02086188PHASE4COMPLETEDStudy of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
NCT02092181PHASE4COMPLETEDA Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson’s Disease (MAESTRO)
NCT02095665PHASE4COMPLETEDUreteral Stent-related Pain and Mirabegron (SPAM) Trial
NCT02138747PHASE4COMPLETEDA Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
NCT02216214PHASE4COMPLETEDStudy to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02279615PHASE4UNKNOWNEfficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
NCT02294396PHASE4COMPLETEDPostmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
NCT02361502PHASE4UNKNOWNMIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02436889PHASE4COMPLETEDTreatment of Incontinence Without Memory Problems
NCT02468375PHASE4COMPLETEDProspective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
NCT02495389PHASE4COMPLETEDMirabegron and Urinary Urgency Incontinence
NCT02536976PHASE4COMPLETEDMirabegron in Parkinson Disease and Impaired Cognition
NCT02540707PHASE4COMPLETEDComparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02656173PHASE4COMPLETEDA Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
NCT02757768PHASE4COMPLETEDA Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
NCT02981459PHASE4WITHDRAWNMirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT03012113PHASE4UNKNOWNMirabegron and Brown Adipose Tissue
NCT03412513PHASE4UNKNOWNMirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson’s Disease
NCT03558919PHASE4COMPLETEDEfficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
NCT03695822PHASE4WITHDRAWNImpact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
NCT04501640PHASE4COMPLETEDA Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants
NCT04562090PHASE4COMPLETEDA Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04907032PHASE4COMPLETEDPosterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
NCT04909255PHASE4UNKNOWNBeta-3 Agonist and Anti-muscarinic Agent for Sjogren’s Syndrome With Overactive Bladder
NCT05188742PHASE4UNKNOWNSequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05452434PHASE4UNKNOWNMirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
NCT05946902PHASE4UNKNOWNComparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
NCT06124066PHASE4COMPLETEDTHE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS
NCT07533565PHASE4COMPLETEDA Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
NCT05621616PHASE3ACTIVE_NOT_RECRUITINGA Study to Learn How Effective and Safe the Drug ‘Mirabegron’ is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
NCT06551246PHASE3RECRUITINGEfficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 8 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

280 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CrizotinibChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
DesloratadineChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
DihydroergotamineChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
PramipexoleChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
RIFAMPINChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
TEGASERODChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2, ADRB3
ARIPIPRAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
BISOPROLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
BROMOCRIPTINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
CARVEDILOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
EPINEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
FENOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
FORMOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
ISOPROTERENOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
LABETALOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
LEVOBUNOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
MONTELUKASTChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
NOREPINEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PHENYLEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PIMOZIDEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PINDOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PRACTOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PROPAFENONEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
PROPRANOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
SALMETEROLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
SOTALOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
TAMOXIFENChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
THIORIDAZINEChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
TIMOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2, ADRB3
ALPRENOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
BOPINDOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
CIMATEROLChEMBLPhase 2ADRB1, ADRB2, ADRB3
FLESTOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
LEVISOPRENALINEChEMBLPhase 2ADRB1, ADRB2, ADRB3
LEVOPROPRANOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
MILVETEROLChEMBLPhase 2ADRB1, ADRB2, ADRB3
RAFABEGRONChEMBLPhase 2ADRB1, ADRB2, ADRB3
SOLABEGRONChEMBLPhase 2ADRB1, ADRB2, ADRB3
TRETOQUINOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
XAMOTEROLChEMBLPhase 2ADRB1, ADRB2, ADRB3
ZENIDOLOLChEMBLPhase 2ADRB1, ADRB2, ADRB3
AlogliptinPubChemApprovedADRB1, ADRB2, ADRB3
BosentanPubChemApprovedADRB1, ADRB2, ADRB3
FidaxomicinPubChemApprovedADRB1, ADRB2, ADRB3
GlycopyrrolatePubChemApprovedADRB1, ADRB2, ADRB3
LinagliptinPubChemApprovedADRB1, ADRB2, ADRB3
MethotrexatePubChemApprovedADRB1, ADRB2, ADRB3
PropoxyphenePubChemApprovedADRB1, ADRB2, ADRB3
PyrazinamidePubChemApprovedADRB1, ADRB2, ADRB3
Tiotropium Bromide MonohydratePubChemApprovedADRB1, ADRB2, ADRB3
CLOZAPINEChEMBL + PubChemPhase 4 (approved)ADRB2, ADRB3
OLANZAPINEChEMBL + PubChemPhase 4 (approved)ADRB2, ADRB3
OLODATEROLChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
TAMSULOSINChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
ACEBUTOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
ALBUTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
AMIODARONEChEMBLPhase 4 (approved)ADRB1, ADRB3
AMITRIPTYLINEChEMBLPhase 4 (approved)ADRB1, ADRB2
AMLODIPINEChEMBLPhase 4 (approved)ADRB2, ADRB3

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot